Abivax: Publication of an expert article in JCC on obefazimod as promising therapeutic management option for UC patients

EQS-News: ABIVAX / Key word(s): Miscellaneous
Abivax: Publication of an expert article in JCC on obefazimod as promising therapeutic management option for UC patients
02.05.2023 / 18:00 CET/CEST
The issuer is solely responsible for the content of this announcement.

Abivax: Publication of an expert article in JCC on obefazimod as promising therapeutic management option for UC patients

• The authors of the expert article published in the Journal of Crohn’s and Colitis include major European and North American Key Opinion Leaders in the field of Inflammatory Bowel Diseases
• The KOLs state that obefazimod is a first-in-class drug with a unique mechanism of action and with great promise in the therapeutic management of ulcerative colitis patients
• The experts expect that the results from the ongoing Phase 3 program with obefazimod in UC will confirm its potential to rapidly and durably relieve patients from their symptoms

PARIS, France, May 2^nd, 2023 – 06:00 p.m. (CEST) – Abivax SA (Euronext Paris: FR0012333284 – ABVX), a Phase 3 clinical-stage biotechnology company focused on developing therapeutics that modulate the immune system to treat patients with chronic inflammatory diseases, today announces the Journal of Crohn’s and Colitis (JCC) publication of a piece titled “Obefazimod: a first-in-class drug for the treatment of ulcerative colitis”[1], written by global Inflammatory Bowel Disease (IBD) experts.

The authors of the publication include major European and North American Key Opinion Leaders (KOLs) in the field of IBD, e.g. Séverine Vermeire (Belgium), Virginia Solitano (Italy and Canada), Laurent Peyrin-Biroulet (France), Herbert Tilg (Austria), Silvio Danese (Italy), and Bruce Sands (United States).

The KOLs conclude, obefazimod is a first-in-class drug with a unique mechanism of action that holds great promise in the therapeutic management of ulcerative colitis (UC) patients. The experts further expect the results from the ongoing Phase 3 program with obefazimod for the treatment of UC (ABTECT program) will confirm the previous outcomes and their conclusions issued in this publication. 

Prof. Hartmut J. Ehrlich, M.D., CEO of Abivax, said. “We are proud of the publication of this expert opinion written by internationally leading KOLs in the field of IBD. The conclusion that obefazimod holds great promise as a novel therapeutic management option for UC patients is very motivating for the Abivax team. We believe we are on the right track to confirm our lead drug candidate’s ability to swiftly and durably relieve UC patients from their symptoms. We are encouraged by the leading KOLs, as well as our investors and partners shared view about the potential of obefazimod and also by the increased interest of the scientific, medical and investment community in our molecule. We are determined to conclude our ongoing Phase 3 program as quickly as possible and make obefazimod available to all UC patients, especially to those who urgently need alternative treatment options.”

Prof. Séverine Vermeire, M.D., Ph.D., Head of the IBD Center at the University Hospitals Leuven, Belgium, and principal investigator of the ABTECT program in Europe, adds: “Our expert analysis took into account all the different aspects of the preclinical and clinical development of obefazimod, including the most recent insights on its unique mechanism of action. We came to the conclusion that obefazimod might change the treatment paradigm of ulcerative colitis and inflammatory bowel diseases in the future. We continue to be impressed by its clinical efficacy, especially in the course of the maintenance treatment as well as by its safety profile. Therefore, we are very interested in completing the Phase 3 program of obefazimod in UC which we believe can confirm the outcomes of the Phase 2a and Phase 2b trials. We urgently need potent and long-term efficient treatments that are well tolerated by the patients and, with obefazimod, we might have such a candidate in our hands.”

The article analyses the results generated in preclinical studies as well as clinical trials conducted with obefazimod in ulcerative colitis, rheumatoid arthritis, Covid-19 and HIV patients. The KOL’s analysis is summarized in the following main conclusions:

• Obefazimod enhances the selective splicing of a single long non-coding RNA to generate an anti-inflammatory microRNA called miR-124. miR-124 is responsible for downregulation of key pro-inflammatory cytokines and chemokines thus exerting its inflammation dampening effects. The sustained overexpression of miR-124 might explain why obefazimod provides a high remission rate in UC patients after one and two years of continued daily dosing. In parallel, miR-124 does not only decrease mucosal inflammation, but it also promotes tissue repair.
• Evidence from Phase 2 clinical trials supports the anti-inflammatory effect of obefazimod. Findings from the maintenance phases of the trials showed that the long-term treatment with the molecule provides continued improvement in clinical symptoms of the disease, with a substantial proportion of patients in clinical remission.
• All clinical studies of obefazimod have shown a consistent and good safety profile, during the induction as well as in the subsequent maintenance trials. The most common treatment-emergent adverse events (TEAEs) were headache and nausea. Headaches occurred early during the first 10 days of treatment, were generally mild to moderate and lasted only a few days. There was no signal of serious infection or malignancies.
• Obefazimod exerted no effect on the immune system in the absence of inflammation, therefore supporting a mechanism of action as modulator of immune cell activation during inflammation but not in its absence. These findings provide evidence that upregulating miR-124 by obefazimod reverses the expression of several pro-inflammatory cytokines triggered during inflammation but does not blunt the immune response altogether.

In order to confirm the fast onset of action, the long-term efficacy results as well as the safety profile that obefazimod generated notably in its Phase 2a and Phase 2b clinical trials for the treatment of UC patients, Abivax is currently conducting an international Phase 3 clinical program (ABTECT).

1,200 patients suffering from moderate to severe UC at 600 investigator sites covering North America, Europe, Latin America and Asia Pacific will be included in the two induction trials (ABTECT-1 and ABTECT-2) followed by a single maintenance trial to confirm obefazimod’s fast onset of action and its long-term efficacy.

Top-line results of the two induction trials are expected to become available by the end of 2024. The results of the single maintenance trial are expected by the end of 2025.

*****

About Abivax (www.abivax.com)

Abivax is a Phase 3 clinical stage biotechnology company, focused on developing therapeutics that modulate the immune system to treat patients with chronic inflammatory diseases. Abivax, founded by Truffle Capital, is listed on Euronext compartment B (ISIN: FR0012333284 – Mnémo: ABVX). Based in Paris and Montpellier, Abivax’s lead drug candidate, obefazimod (ABX464), is in Phase 3 clinical trials for the treatment of ulcerative colitis. More information on the company is available at www.abivax.com. Follow us on Twitter @ABIVAX_.

Contacts

DISCLAIMER

This press release contains forward-looking statements, forecasts and estimates (including patient recruitment) with respect to certain of the Company's programs. Although Abivax’ management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks, contingencies and uncertainties, many of which are difficult to predict and generally beyond the control of Abivax, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. A description of these risks, contingencies and uncertainties can be found in the documents filed by the Company with the French Autorité des Marchés Financiers pursuant to its legal obligations including its registration document (Document d’Enregistrement Universel). These risks, contingencies and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates. Special consideration should be given to the potential hurdles of clinical and pharmaceutical development including further assessment by the company and regulatory agencies and IRBs/ethics committees following the assessment of preclinical, pharmacokinetic, carcinogenicity, toxicity, CMC and clinical data. Furthermore, these forward-looking statements, forecasts and estimates are only as of the date of this press release. Readers are cautioned not to place undue reliance on these forward-looking statements. Abivax disclaims any obligation to update these forward-looking statements, forecasts or estimates to reflect any subsequent changes that the Company becomes aware of, except as required by law. Information about pharmaceutical products (including products currently in development) which is included in this press release is not intended to constitute an advertisement. This press release is for information purposes only, and the information contained herein does not constitute either an offer to sell, or the solicitation of an offer to purchase or subscribe securities of the Company in any jurisdiction, in particular in France. Similarly, it does not give and should not be treated as giving investment advice. It has no connection with the investment objectives, financial situation or specific needs of any recipient. It should not be regarded by recipients as a substitute for exercise of their own judgement. All opinions expressed herein are subject to change without notice. The distribution of this document may be restricted by law in certain jurisdictions. Persons into whose possession this document comes are required to inform themselves about and to observe any such restrictions.

^[1] Vermeire et al.: Obefazimod: a first-in-class drug for the treatment of ulcerative colitis, JCC, published online in May 2023 (DOI: 10.1093/ecco-jcc/jjad067).

02.05.2023 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com